Teza Capital Management LLC Sells 1,321 Shares of Humana Inc. (NYSE:HUM)

Teza Capital Management LLC trimmed its position in Humana Inc. (NYSE:HUM) by 24.2% in the 4th quarter, Holdings Channel reports. The firm owned 4,140 shares of the insurance provider’s stock after selling 1,321 shares during the quarter. Teza Capital Management LLC’s holdings in Humana were worth $1,050,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in Humana in the 4th quarter valued at $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA raised its position in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana during the 4th quarter valued at $33,000. Finally, Transce3nd LLC purchased a new stake in shares of Humana during the 4th quarter valued at $38,000. 92.38% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HUM. Royal Bank of Canada restated an “outperform” rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. StockNews.com upgraded shares of Humana from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Truist Financial lowered their price objective on shares of Humana from $325.00 to $305.00 and set a “hold” rating on the stock in a research report on Monday, May 12th. Mizuho raised their price objective on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday, April 9th. Finally, Oppenheimer raised their price objective on shares of Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $286.81.

Humana Price Performance

HUM stock opened at $237.42 on Monday. The firm’s 50-day moving average price is $262.94 and its two-hundred day moving average price is $269.57. Humana Inc. has a 12-month low of $212.45 and a 12-month high of $406.46. The stock has a market capitalization of $28.65 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.05 and a beta of 0.49. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm had revenue of $32.11 billion for the quarter, compared to analysts’ expectations of $32 billion. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $7.23 earnings per share. As a group, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s payout ratio is 25.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.